Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2009

View Archived Issues

Recent Roche patent describes new NNRTIs for HIV infection

GlaxoSmithKline divulges new calcium receptor antagonists for osteoporosis

New CaSR antagonists discovered by Pfizer researchers

Novel microtubule-stabilizing agents discovered by the University of Pennsylvania and Kosan

Novel tachykinin NK1 receptor antagonists identified by Merck & Co. researchers

Recent Takeda patent reports new renin inhibitors with antihypertensive properties

Synta completes enrollment in phase III SYMMETRYSM trial

Auxilium completes enrollment in phase IIb Xiaflex trial

Phase II IMPACT-DCM clinical trial of Aastrom's CRCs placed on clinical hold after SAE

New DPP-4 inhibitors discovered by Santhera and Biovitrum researchers

Rexahn initiates phase IIa clinical trial of Serdaxin in major depressive disorder

Cephalon exercises option to license worldwide rights to ImmuPharma's Lupuzor for SLE

Researchers report development of tetracyclic indole inhibitors of HCV NS5B-polymerase

Medarex receives milestone payment from MedImmune for allowance of IND for MEDI-546

Drug delivery innovation: Selective release of DNA oligonucleotides from gold nanorods with lasers

Acorda submits NDA for Fampridine-SR for walking improvement in MS

Cenix collaborates with Boehringer Ingelheim for RNAi-based target discovery

Idera achieves clinical milestone under cancer collaboration with Merck KGaA

Anavex scales up Anavex 2-73 for phase I Alzheimer's disease study

Ligand announces phase IIb results for PS4-33540 in hypertension

Phase III study shows Tarceva plus Avastin improves survival in lung cancer

Safinamide significantly improved motor function in Parkinson's disease

Medgenics presents positive data from phase I/II Epodure trial in anemia

ESBATech advances antibody fragment into phase Ib/IIa trials in ophthalmology

Transcept completes merger with Novacea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...